Resource Files
Shaping the Management of Parkinson's Disease
- How to Claim Credit
- 0900 Mari Debate (AGREE)
- 0900 Fox Debate (DISAGREE)
- 1000 Mestre Debate (AGREE)
- 1000 Simuni Debate (DISAGREE)
- 1130 Wills Debate (AGREE)
- 1130 Siderowf Debate (DISAGREE)
- 1230 LeWitt Debate (AGREE)
- 1230 Schwarzschild Debate (DISAGREE)
- 1400 Bronte-Stewart Debate (AGREE)
- 1400 Merola Debate (DISAGREE)
- 1500 How to design a clinical trial in COVID times Fernandez
- 0900 York Debate (AGREE)
- 0900 Alcalay Debate (DISAGREE)
- 1000 Update On Genetics In Parkinson Disease Nance
- 1100 Progess in Behavioral and Non-Motot Therapies in PD Pontone
- 1145 New “On-Demand” Therapies For PD Pagan
Resource Links
Agenda
January 23, 2021
| 8:30 AM | Sign on and Exhibits |
| 8:55 AM | Introduction and Welcome Remarks Hubert Fernandez |
| Moderator: | Marie Saint-Hilaire |
| 9:00 AM | Convention vs Innovation I: Telemedicine/Virtual Visits Should Now Be A Preferred Option For Following Patients With PD After Diagnosis |
| Agree : Zoltan Mari | |
| Disagree : Susan Fox | |
| 10:00 AM | Convention vs Innovation II: Time To Abandon Clinician-Administered Scales As The Primary Outcome Measure Of Symptomatic And Disease Modifying Trials in Parkinson's Disease |
| Agree : Tiago Mestre | |
| Disagree : Tanya Simuni | |
| 11:00 AM | Break/Exhibits |
| Moderator: |
Liana Rosenthal |
| 11:30 AM |
Nature vs. Nurture ENCORE topic: Genetically-Targeted Trials And Not Immunotherapy-Based Trials Will Lead Us To Our First Successful Disease Modifying Therapy |
| Agree : Anne-Marie Willis | |
| Disagree : Andrew Siderowf |
|
| 12:30 PM | Hope vs. Hype I: Istradefylline's "non-dopaminergic" Mechanism of Action Provides a Unique And Significant Advantages in PD Treatment |
| Agree : Peter LeWitt | |
| Disagree : Michael Schwarzschild | |
| 1:30 PM | Break/Exhibits |
| 2:00 PM | Hope vs. Hype II: Closed Loop Technology Will Provide More Meaningful Improvement vs. Directional Leads In Deep Brain Stimulation |
| Agree : Helen Bronte-Stewart | |
| Disagree : Aristide Merola | |
| 3:00 PM | How to Design A Clinical Trial in COVID-19 Times Hubert Fernandez |
| 4:00 PM | ADJOURN |
January 24, 2021
| 8:30 AM |
Sign on and Exhibits |
| 8:55 AM | Welcome Remarks Michael Schwarzchild |
| Moderator: | Allison Willis |
| 9:00 AM | Enough vs More: Neuropsychological Testing is More Useful Than Genetic Testing In The Baseline PD Evaluation |
| Agree : Michele York |
|
| Disagree : Roy Alcalay | |
| 10:00 AM | Update on Genetics in Parkinson's Disease Martha Nance |
| 10:45 AM | Break/Exhibits |
| Moderator: | Hubert Fernandez |
| 11:00 AM | Progress in Behavioral And Non-Motor Therapies in PD Gregory Pontone |
| 11:45 AM | New "On-Demand" Therapies For PD: Racing a Thoroughbred Horse, or Beating a Dead One? Fernando Pagan |
| 12:30 PM | Break/Exhibits CME Program Adjourns |
| 1:00 PM - 1:45 PM | Optional Non-CME Session: The Most Promising Symptomatic Trials in PD William Ondo |